IRB# 22805: A Phase 0 Master Protocol Using the CIVO Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients with Solid Tumors

IRB# 21518: Evaluation of TAK-981 and TAK-981 Combinations Following Intratumoral CIVO* Microdosing in Patients with Head and Neck Cancer

IRB# 21902: A Phase 2 Multi-center pharmacodynamic study to assess the effects of multiple study drug regimens in subjects with newly diagnosed locally advanced head and neck squamous cell carcinoma

IRB# 23008: Gilead
A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

IRB# 23008: Gilead
A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

IRB# 23008: Gilead
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

IRB# 24158 SGCTN-001
A Phase 2 Study of ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma

IRB# 24233 ASPEN03
A Phase 2 Study of ALX148 In Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma

IRB# 24158 SGCTN-001
A Phase 2 Study of ALX148 In Combination with Pembrolizumab

IRB# 23008
A Phase 2 Study of ALX148

IRB# 21902: Digital Intervention Protocol to Enhance Recovery after Head and Neck Surgery: A Randomized Controlled Trial

11 July 2022

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result